Identification of novel genetic Loci associated with thyroid peroxidase antibodies and clinical thyroid disease
- PMID: 24586183
- PMCID: PMC3937134
- DOI: 10.1371/journal.pgen.1004123
Identification of novel genetic Loci associated with thyroid peroxidase antibodies and clinical thyroid disease
Abstract
Autoimmune thyroid diseases (AITD) are common, affecting 2-5% of the general population. Individuals with positive thyroid peroxidase antibodies (TPOAbs) have an increased risk of autoimmune hypothyroidism (Hashimoto's thyroiditis), as well as autoimmune hyperthyroidism (Graves' disease). As the possible causative genes of TPOAbs and AITD remain largely unknown, we performed GWAS meta-analyses in 18,297 individuals for TPOAb-positivity (1769 TPOAb-positives and 16,528 TPOAb-negatives) and in 12,353 individuals for TPOAb serum levels, with replication in 8,990 individuals. Significant associations (P<5×10(-8)) were detected at TPO-rs11675434, ATXN2-rs653178, and BACH2-rs10944479 for TPOAb-positivity, and at TPO-rs11675434, MAGI3-rs1230666, and KALRN-rs2010099 for TPOAb levels. Individual and combined effects (genetic risk scores) of these variants on (subclinical) hypo- and hyperthyroidism, goiter and thyroid cancer were studied. Individuals with a high genetic risk score had, besides an increased risk of TPOAb-positivity (OR: 2.18, 95% CI 1.68-2.81, P = 8.1×10(-8)), a higher risk of increased thyroid-stimulating hormone levels (OR: 1.51, 95% CI 1.26-1.82, P = 2.9×10(-6)), as well as a decreased risk of goiter (OR: 0.77, 95% CI 0.66-0.89, P = 6.5×10(-4)). The MAGI3 and BACH2 variants were associated with an increased risk of hyperthyroidism, which was replicated in an independent cohort of patients with Graves' disease (OR: 1.37, 95% CI 1.22-1.54, P = 1.2×10(-7) and OR: 1.25, 95% CI 1.12-1.39, P = 6.2×10(-5)). The MAGI3 variant was also associated with an increased risk of hypothyroidism (OR: 1.57, 95% CI 1.18-2.10, P = 1.9×10(-3)). This first GWAS meta-analysis for TPOAbs identified five newly associated loci, three of which were also associated with clinical thyroid disease. With these markers we identified a large subgroup in the general population with a substantially increased risk of TPOAbs. The results provide insight into why individuals with thyroid autoimmunity do or do not eventually develop thyroid disease, and these markers may therefore predict which TPOAb-positives are particularly at risk of developing clinical thyroid dysfunction.
Conflict of interest statement
I have read the journal's policy and have the following conflicts: Dr. Bruce M Psaty reported serving on a DSMB for a clinical trial of a device funded by the manufacturer (Zoll LifeCor) and on the Yale Open Data Access Project funded by Medtronic. All other authors have declared that no competing interests exist.
Figures
References
-
- Gough SC (2000) The genetics of Graves' disease. Endocrinol Metab Clin North Am 29: 255–266. - PubMed
-
- Tunbridge WM, Evered DC, Hall R, Appleton D, Brewis M, et al. (1977) The spectrum of thyroid disease in a community: the Whickham survey. Clin Endocrinol (Oxf) 7: 481–493. - PubMed
-
- Biondi B (2012) Mechanisms in endocrinology: Heart failure and thyroid dysfunction. Eur J Endocrinol 167: 609–618. - PubMed
Publication types
MeSH terms
Substances
Supplementary concepts
Grants and funding
- UL1 RR033176/RR/NCRR NIH HHS/United States
- N01 HC085080/HL/NHLBI NIH HHS/United States
- U01 HL080295/HL/NHLBI NIH HHS/United States
- R01 HL087652/HL/NHLBI NIH HHS/United States
- R01 HL105756/HL/NHLBI NIH HHS/United States
- HHSN268201200036C/HL/NHLBI NIH HHS/United States
- N01 HC055222/HL/NHLBI NIH HHS/United States
- N01 HC085079/HL/NHLBI NIH HHS/United States
- R01 HL080295/HL/NHLBI NIH HHS/United States
- P30 CA016058/CA/NCI NIH HHS/United States
- DK063491/DK/NIDDK NIH HHS/United States
- WT_/Wellcome Trust/United Kingdom
- HL080295/HL/NHLBI NIH HHS/United States
- N01 HC085081/HL/NHLBI NIH HHS/United States
- UL1RR033176/RR/NCRR NIH HHS/United States
- UL1TR000124/TR/NCATS NIH HHS/United States
- N01 HC085082/HL/NHLBI NIH HHS/United States
- R01 HG002651/HG/NHGRI NIH HHS/United States
- HL105756/HL/NHLBI NIH HHS/United States
- N01 HC085086/HL/NHLBI NIH HHS/United States
- N01 HC085083/HL/NHLBI NIH HHS/United States
- 085541/Z/08/Z/WT_/Wellcome Trust/United Kingdom
- HL087652/HL/NHLBI NIH HHS/United States
- UL1 TR000124/TR/NCATS NIH HHS/United States
- P30 DK063491/DK/NIDDK NIH HHS/United States
- P30 CA16058/CA/NCI NIH HHS/United States
- WT089062/WT_/Wellcome Trust/United Kingdom
- P01 CA124570/CA/NCI NIH HHS/United States
- R01 AG023629/AG/NIA NIH HHS/United States
- AG023629/AG/NIA NIH HHS/United States
- R56 AG023629/AG/NIA NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
